Catalyst Wire Dossier Catalyst Wire Dossier

Anti-malarial agents platform study (Cohort B2)

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-malarial agents platform study (Cohort B2), covering 2026-03-13 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) [Phase 2]

See pricing